Navigating Prostate Cancer Therapy. Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA
|
|
- Annabella Atkinson
- 5 years ago
- Views:
Transcription
1 Navigating Prostate Cancer Therapy Nevin Murray MD Clinical Professor of Medicine, UBC Medical Oncologist, BCCA
2 Disclosures In compliance with accreditation, we require the following disclosures to the session audience: Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board N/A N/A N/A N/A N/A AstraZeneca, Bristol Myers Squibb, Astellas AstraZeneca, Bristol Myers Squibb, Astellas Presentation includes discussion of the following off- label use of a drug or medical device: N/A
3 Prostate Cancer Demographics In Canada in ,000 new cases (#1 overall) 4,100 deaths (#3 in men) In B.C. in ,800 new cases (#1 overall) 600 deaths (#3 in men)
4 Prostate Cancer Screening Review of new studies Why does a clear consensus escape us? Randomized trials but no easy answer. Current recommendations And what to do in Family Medicine
5 Summary Gary Larson Far Side
6 The evidence Comes from 2 Randomized Studies Europe - ERSPC USA - PLCO NEJM March 2009
7 ERSPC European Randomized Screening Trial of Prostate Cancer 162,400 men in core group years Median follow-up 11 years Control group not screened Screened group: PSA every 4 years x 2 PSA threshold 3ng/ml (2.5-4ng/ml) DRE dropped control screened Positive diagnosis rate 6% 9.6% (63% increase) Schroder et al. N Engl J Med, 360,(13), 2009 & March 2012
8 Results: ERSPC trial Large stage shift (% of positive) control screened High risk 13% 8% Metastases 8.2% 3% (48% decrease) Non-palpable (T1c) 41% 54% (31% increase) Schroder NEJM March 2009 & March 2012, Supplemental material on line, adjusted for null stage
9 Update: ERSPC trial And this translates into a reduction in prostate cancer deaths Screened 0.4% (n=299) Control 0.5% (n=462) RR 0.79 p=0.001 Schroder: NEJM March 15, 2012
10 Update: ERSPC trial NNInvite 781 (was 1440) NNDiagnose 27 (was 48) In those actually screened Mortality reduction ratio 0.71 But no hint of an overall survival benefit Mortality ratio 0.99 [CI ] Schroder EAU Paris 2012
11 Update: PLCO trial Prostate Cancer Mortality Cumulative number of deaths Screened Control Study year of death Redrawn from Andriole JNCI On line 2012
12 Why the differences? In the US the baseline opportunistic screening rate was 45% in the prior 3 years (lifetime rate unknown) rising to 52% in the control arm by year 6 and 86% in the screening arm So it was a trial of more screening versus ~50% screening
13 Indicative of an underlying problem PSA is not a great test! Significant overlap No level free of cancer risk Holmström,BMJ 2009;339:b3537
14 PSA: No safe level Thompson. JCO VOLUME 23 NUMBER 32 NOVEMBER
15 PSA screening in Family Practice 93% are screening Bluman et al Primary Care Physician Education and Engagement in the Promotion of Recommended Cancer Screening in BC Report On Province-wide Cancer Screening Needs Assessment UBC Division of Continuing Professional Development, Faculty of Medicine & The BC Cancer Agency Widely available through Google search
16 What is the BCCA policy? May 2012 We recommend: Considering PSA Testing Start age: asymptomatic men years estimated life expectancy > 10 years well informed about the risks of over-diagnosis and over-treatment BCCA web site: Google BCCA PSA Screening
17 1: Asymptomatic men years Tempting to get a baseline level at But not evidence based Costly Many false positives Possibly indicated in the high risk Family history African ethnicity
18 2: Well informed about the risks of over-diagnosis and over-treatment This is really difficult It is impossible to do properly in 5 minutes Is it actually required ethically? Do we do this for cholesterol testing? An easy out to say no! Most authorities say it is required Patient information brochures are available And should be read before the blood is drawn Wolf AM, Wender RC, Etzioni RB, et al. American Cancer Society guideline for the early detection of prostate cancer: update CA Cancer J Clin Mar- Apr;60(2):70-98.
19 Minimum components of consent Risks of PSA testing False negative and false positive PSA results A low PSA test does not mean that a person does not have prostate cancer, and a high PSA does not necessarily mean a person does have prostate cancer. Biopsy Pain and very rarely infection. Distress and anxiety Being diagnosed with prostate cancer is associated with anxiety. Over-diagnosis and treatment Over-diagnosis refers to the detection of cancers that would not otherwise have become clinically apparent. This could result in treatment of a prostate cancer that may not have been a problem for a man in his lifetime The risks of treatment such as radiation and surgery include urinary problems and incontinence, sexual dysfunction, and bowel problems. BCCA web site: Google BCCA PSA Screening
20 Minimum components of consent Benefits Early detection of prostate cancer can save lives. Early detection and treatment of prostate cancer can avert future prostate cancer-related problems. BCCA web site: Google BCCA PSA Screening
21 How to do it: If the patient wants it Every 4 years starting (45 if high risk) Any PSA that is high (age-adjusted) needs 1. Checking 2. Then referral to a Urologist Or abnormal DRE Refer to a Urologist Stop when life expectancy <10 years
22 Summary Small decrease in prostate cancer mortality At a cost of probable overall net harm Patients should be informed of its availability And make their own decision With your guidance Watch out for normal PSA s that are high for age >1 ng/ml in 40 s >2 ng/ml in 50 s Refer promptly if abnormal PSA Those with <10 yr life expectancy should not be screened
23 Localized Prostate Ca BCCA Promotes Active Surveillance Monitoring of low risk cancer with intervention if the cancer progresses to intermediate risk Low risk: PSA 10 and Gleason score 6 Of BCCA patients referred to Rad Onc last year 1/3 had low risk prostate cancer 2/3 of these had no immediate treatment 2/3 of those will avoid treatment for 5 years
24 LOW RISK RESULTS Weighted >40 months follow-up or less than 100 patients Treatment Success % PSA Progression Free HDR Proton EBRT/IMRT 11/16/2015 Update of BJU Int, 2012, Vol. 109(Supp 1) Years from Treatment Prostate Cancer Results Study Group Numbers within symbols refer to references Prostate Cancer Center of Seattle 5 LDR Brachy 16 Surgery Seeds & ADT EBRT & ADT EBRT & Seeds Robot RP Seeds Surgery EBRT CRYO HIFU Protons Hypo EBRT HDR 24
25 Management Objective of Metastatic Cancer incurable. Prostate Cancer Have patient live as well as possible, and as long as possible in co-existance with metastatic prostate cancer. Use available systemic therapy cost-effectively at appropriate time, keeping side effects to a minimum.
26 THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND CHARLES HUGGINS, M.D.; R. E. STEVENS, Jr., M.D.; CLARENCE V. HODGES, M.D. Arch Surg. 1941;43(2): In this paper evidence is presented that significant improvement often occurs in the clinical condition of patients with far advanced cancer of the prostate after they have been subjected to castration. Conversely, the symptoms are aggravated when androgens are injected. We believe that this work provides a new concept of prostatic carcinoma. Charles B. Huggins Nobel Prize in Physiology or Medicine 1966
27 The Predominate Sources of Androgen ~90% androgen synthesis Testes In healthy men, ~90% of circulating androgens are synthesized in the testes ~10% androgen synthesis Adrenal Gland ~10% of circulating androgens are secreted by the adrenals DHT is the primary androgen in prostatic tissue Hoimes CJ, et al. Ther Adv Med Oncol. 2010;2:
28 Androgens Drive Prostatic Tumor Growth LHRH therapy or orchiectomy may be used to suppress testicular sources of androgen LHRH therapy or orchiectomy Adrenal Gland Prostatic Tumor Tissue Treatment with LHRH therapy or orchiectomy is used to induce regression of prostate tumor tissue and cause cell death; however, it is rarely curative Hoimes CJ, et al. Ther Adv Med Oncol. 2010;2:
29 Primary Androgen Deprivation Therapy Orchiectomy Cheap Permanent Medical vs surgical side effects similar LHRH Agonists Injections every one to six months. Requires biclutamide x 1 month to avoid flare. Home Care programs. Intermittent strategy LHRH Antagonists Monthly injections. Works faster. No flare or need for biclutamide for this purpose.
30 Intermittent ADT PR.7: Non-Metastatic PR.8: Metastatic JM Crook et al, NEJM367:895, 2013; M. Hussain et al, NEJM, 368:1314, 2013
31 Many options currently available to inhibit extragonadal androgen production or androgen receptors Biclutamide, nilutamide, flutamide Prednisone 10 mg daily Dexamethasone 2 mg daily Clinical Impact? But... 2 nd Line Hormone Therapy PSA response rate 20-30% TTP/duration of response 3-6 months Survival and clinical benefit have never been well defined Are we changing natural history? Well tolerated, inexpensive Some very good PSA and symptomatic responses Appropriate for patients with minimal symptoms, no visceral metastases and chemotherapy-ineligible Big Guns kept in reserve for when really needed.
32 Defining The Patient Population: Castration Resistant Prostate Cancer Aka: Hormone Refractory, Androgen Independent Prostate Cancer Clinical Trials Working Group: Castrate level of testosterone (<50 ng/dl/1.7 nmol/l) Nodal or visceral progression Bone Progression: appearance of 2 or more new lesions Heterogenous Group No clinical metastases Clinical metastases Asymptomatic Symptomatic PSA Rise Biochemical Clinical Metastases Symptomatic Disease Death 36+ Months Months Months
33 Prostate Cancer Before 1996 Localized Local Relapse Treat with curative intent Failed Localized Therapy Hormone Therapy (incurable) Death Biochemical Progression A whole lot of nothing Metastatic HRPC (asympt.) prednisone Metastatic HRPC (sympt)
34 Systemic Therapies
35 Cytotoxic Therapy for Castration-Resistant Prostate Cancer
36 Assessing Response to Chemotherapy Most men with metastatic prostate cancer have bone metastases. Soft Tissue Disease on CT Scan Lymph nodes, liver, lung. Necessary to rely on surrogate endpoints to assess response decline in serum PSA, LDH. improvement in pain QOL
37 Timing of Chemotherapy Many patients who have disease progression following androgen-deprivation therapy do not immediately require cytotoxic chemotherapy Not for PSA relapse only Not for clinically silent metastatic disease Performance status reserve required Consider PSA doubling time in borderline case
38 TAX-327 Stratification: Pain level PPI 2 or AS 10 vs. PPI < 2 or AS < 10 KPS 70 vs. 80 R A N D O M I Z E Docetaxel 75 mg/m 2 q3 wks + Prednisone 5 mg bid Docetaxel 30 mg/m 2 wkly 5 of 6 wks + Prednisone 5 mg bid Mitoxantrone 12 mg/m 2 q3 wks + Prednisone 5 mg bid Overall Survival Tannock et al., NEJM, 2004 (slide courtesy of Dr. K. Chi)
39 TAX-327 Overall Survival Probability of Surviving Median survival Hazard (mos) ratio P-value Combined: D 3 wkly: D wkly: Mitoxantrone 16.4 Docetaxel 3 wkly Docetaxel wkly Mitoxantrone Tannock et al., NEJM, 2004 (slide courtesy of Dr. K. Chi)
40 STRATIFICATION Extent of Mets -High vs Low Age 70 vs < 70yo ECOG PS vs 2 CAB> 30 days -Yes vs No SRE Prevention -Yes vs No Prior Adjuvant ADT 12 vs > 12 months NEJM, 373: 737, 2015 R A N D O M I Z E ARM A: ADT + Docetaxel 75mg/m2 every 21 days for maximum 6 cycles ARM B: ADT (androgen deprivation therapy alone) Evaluate every 3 weeks while receiving docetaxel and at week 24 then every 12 weeks Evaluate every 12 weeks ADT allowed up to 120 days prior to randomization. Intermittent ADT dosing was not allowed Standard dexamethasone premedication but no daily prednisone High volume: visceral metastases and/or 4 or more bone metastases (at least 1 beyond pelvis and vertebral column) Follow for time to progression and overall survival Chemotherapy at investigator s discretion at progression
41 CHAARTED: Overall Survival
42 Summary Addition of docetaxel x 6 cycles to initial ADT improves overall survival in patients with metastatic disease: a new standard of care Recommended in patients with high volume metastases ( 4 bone mets with 1 outside spine/pelvis or visceral mets) or poor prognosis Consider in patients with non-high volume disease/good prognosis but risk vs. benefit ratio needs to be considered Do not consider in patients without metastatic disease
43 TAX-327 Overall Survival Probability of Surviving Median survival Hazard (mos) ratio P-value Combined: D 3 wkly: D wkly: Mitoxantrone 16.4 Docetaxel 3 wkly Docetaxel wkly Mitoxantrone Tannock et al., NEJM, 2004 (slide courtesy of Dr. K. Chi)
44 2 nd Line Chemotherapy Patients are older, and generally more symptomatic The expectation is for short duration of survival, so emphasis on QOL and symptom management is paramount Consider repeat docetaxel for good responders Cabizitaxel in robust patients Mitoxantrone weak
45 Abiratirone acetate Enzalutamide New Pills for CRPC
46 Mechanism of Action: Abiratirone Inhibits Androgen Production at Multiple Sites Zytiga inhibits the CYP17 enzyme complex that is required for testosterone biosynthesis in all three sites: Testes Adrenal Gland Prostate Tumor Tissue Testes LHRH Therapy Orchiectomy Prostatic Tumor Tissue Abiraterone acetate Adrenal Gland
47 Sites of Abiratirone Acetate Action in Steroidogenesis Pathway Cholesterol Pregnenolone Aldosterone Abiraterone CYP17A1 17OH- Pregnenolone CYP17A1 Cortisol DHEA Androstenedione Testosterone DHT
48 Mechanism of Action: Effect on Adrenal Function Blocking the CYP17 enzyme also causes decreased cortisol levels This Leads to ACTH increase Resulting in excess aldosterone (Mineralocorticoids) Can cause hypertension, hypokalemia and fluid retention Prednisone X Co-administration of a corticosteroid suppresses ACTH drive, resulting in a reduction in the incidence and severity of mineralocorticoid adverse reactions
49 Abiratirone : Need for Prednisone Low-dose steroid replacement reduces mineralocorticoid-related toxicity Cholesterol No Prednisone Prednisone Pregnenolone Progesterone DOC Corticosterone Aldosterone SALT Mineralocorticoids T CYP17 17α-hydroxylase T Abiraterone HTN Low K+ 17α-OHpregnenolone 17α OHprogesterone 11-Deoxycortisol Cortisol SUGAR Glucocorticoids T CYP17 C17,20-lyase T Abiraterone DHEA Androstenedione Testosterone DHT SEX Androgens Estradiol Source: Attard et al. J Clin Oncol. 2008;26: ; Ryan et al. J Clin Oncol. 2010;28:
50 COU-AA-301 Study Design Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled study (147 sites in 13 countries; USA, Europe, Australia, Canada) 1195 patients with progressive, mcrpc Failed 1 or 2 chemotherapy regimens, one of which contained docetaxel Randomised 2:1 Stratification by: ECOG performance status (0-1 vs. 2) Worst pain over previous 24 hours (BPI short form; 0-3 [absent] vs [present]) Prior chemotherapy (1 vs. 2) Type of progression (PSA only vs. radiographic progression with or without PSA progression) Abiraterone acetate 1000 mg daily Prednisone 5mg twice daily Placebo daily Prednisone 5mg twice daily T R E A T U N T I L P R O G R E S S I O N Primary endpoint: OS (25% improvement; HR 0.8) de Bono et al. N Engl J Med 2011; 346(21):
51 Abiraterone Acetate Improves Overall Survival in mcrpc 100 Hazard ratio = ( ) P < Survival (%) Placebo: 10.9 months (95% CI, ) AA Placebo Abiraterone acetate: 14.8 months (95% CI, ) Time to Death (Months) AA Placebo V2.0 de Bono et al. Ann Oncol 2010: Abstract LBA5 (Oral presentation at ESMO) Scher et al. J Clin Oncol 2011; 29(7S):Abstract 4 (Oral presentation at ASCO GU )
52 Novel Study Design: Co-primary End Points Patient Population Progressive mcrpc without prior chemotherapy; Asymptomatic or mildly symptomatic R A N D O M I Z E D 1:1 a a Stratification by ECOG PS 0 vs 1. Study COU-AA-302 Abiraterone 1000 mg daily + Prednisone 5 mg BID (actual n = 546) Placebo daily + Prednisone 5 mg BID (actual n = 542) Co-primary end points: rpfs (central review) OS Secondary end points: Time to opiate use Time to initiation of chemotherapy Time to ECOG PS deterioration Time to PSA progression Exploratory end points: HR-QoL (FACT-P, BPI- SF) BID, twice daily; rpfs, radiographic progression free survival; OS, overall survival; HR-QoL, Health-related quality of life; FACT-P, Functional Assessment of Cancer Therapy-Prostate; BPI-SF, Brief Pain Inventory-Short Form; ECOG PS, Eastern Cooperative Oncology Group performance status; PSA, prostate-specific antigen. Rathkopf D, ASCO GU 2013, Oral Presentation/ Abstract 5
53 MDV3100: Enzalutamide AR antagonist 8 fold higher affinity than bicalutamide NO DNA binding NO partial agonist activity Chen et al Lancet Oncol. 2010
54 AFFIRM: A Phase 3 Trial of Enzalutamide vs. Placebo in Post-Chemotherapy Treated Castration-Resistant Prostate Cancer (CRPC) TOC Scher HI, et al. N Engl J Med. 2012;367: For Educational Purposes Only Not For Promotional Use
55 AFFIRM Overall Survival TOC HR = 0.63 (95% CI: 0.53, 0.75); p < % Reduction in Risk of Death Overall Survival, % Placebo: 13.6 months (95% CI: 11.3, 15.8) Enzalutamide: 18.4 months (95% CI: 17.3, NYR) No. at Risk Enzalutamide Placebo Months NYR: not yet reached Scher HI, et al. N Engl J Med. 2012;367: For Educational Purposes Only Not For Promotional Use
56 AFFIRM Adverse Events TOC Any Grade Enzalutamide (n = 800) Placebo (n = 399) Frequent Adverse Events More Common with Enzalutamide* Grades 3 Enzalutamide (n = 800) Placebo (n = 399) Fatigue 34% 29% 6% 7% Diarrhea 21% 18% 1% <1% Hot Flash 20% 10% 0% 0% Musculoskeletal pain 14% 10% 1% <1% Headache 12% 6% <1% 0% Adverse Events of Special Interest Any Cardiac Disorders 6% 8% 1% 2% Myocardial Infarction <1% <1% <1% <1% LFT Abnormalities 1% 2% <1% <1% Seizure <1% 0% <1% 0% *Adverse events that occurred in >10% of patients in the enzalutamide group and that occurred in the enzalutamide group at a rate that was at least 2% points higher than that in the placebo group. Grade 4 and 5 events were not observed. Abnormalities on liver-function testing (LFT) included hyperbilirubinemia and increased levels of AST or ALT Scher HI, et al. N Engl J Med. 2012;367: For Educational Purposes Only Not For Promotional Use
57 PREVAIL: A Safety and Efficacy Study of Oral Enzalutamide in Chemotherapy-Naïve Patients With Progressive Metastatic Prostate Cancer Enrollment Complete n = 1680 mcrpc asymptomatic or mildly symptomatic progression after ADT R 1:1 Enzalutamide 160 mg qd Placebo qd PREVAIL is a phase 3, randomized, double-blind, placebo-controlled trial Co-primary endpoints: overall survival and progression-free survival Planned Evaluations Overall survival / Radiographic PFS Time to first SRE Initiation of cytotoxic chemotherapy QoL (FACT-P, EQ-5D) PSA progression Pain palliation (BPI-SF) Safety (AEs, vital signs, physical exam, lab evaluations, ECG) Pharmacokinetics Long-term follow-up (radiographic PFS, SREs, additional therapies for prostate cancer, OS) Subgroups (NCT ) 58
58 Abiraterone vs. Enzalutamide Sequencing Study A phase 2, randomized, multicenter study Whole Blood: cfdna Collection RNA Collection Whole Blood: cfdna Collection RNA Collection Whole Blood: cfdna Collection RNA Collection R A N D O M I S E n = 59 n = 59 1 ST LINE THERAPY 2 ND LINE THERAPY ARM A ABIRATERONE + PREDNISONE ENZALUTAMIDE ARM B P S A P R O G R E S S I O N ARM A CROSS-OVER TO ENZALUTAMIDE CROSS-OVER TO ABIRATERONE + PREDNISONE ARM B CONTINUE UNTIL CLINICAL PROGRESSION CONTINUE UNTIL CLINICAL PROGRESSION ClinicalTrials.gov: NCT
59 Radium-223 Ca Ra Radium-223 α-particles cause double-strand DNA breaks in nearby tumor cells Limited penetration of α-particles (~ 2-10 cell diameters) results in localized area of effect
60 ALSYMPCA: Study Design PATIENTS STRATIFICATION TREATMENT Confirmed symptomati c CRPC 2 Bone metastases No known visceral metastases Postdocetaxel, unfit for docetaxel, or refused docetaxel a Total ALP: <220 U/L vs 220 U/L Bisphosphonate use: Yes vs no Prior docetaxel: Yes vs no R A N D O M I Z E 2:1 N = Injections at 4-week intervals Radium 223 dichloride (50 kbq/kg IV) + Best standard of care b Placebo (saline) + Best standard of care b 136 Centers in 19 countries Planned follow-up is 3 years ALP, alkaline phosphatase; ALSYMPCA, ALpharadin in SYMptomatic Prostate CAncer; CRPC, castration-resistant prostate cancer; IV, intravenous. a Unfit for docetaxel includes patients who were ineligible for docetaxel, refused docetaxel, or lived where docetaxel was unavailable. b Best standard of care is defined as a routine standard of care at each center, eg, local external beam radiation therapy, corticosteroids, antiandrogens, estrogens (eg, stilbestrol), estramustine, or ketoconazole. From supplementary appendix. Parker C, et al. N Engl J Med. 2013;369:
61 Radium-223: ALSYMPCA Trial C. Parker et al, NEJM, 369:213, 2013
62 Radium-223: ALSYMPCA Trial C. Parker et al, NEJM, 369:213, 2013
63 An Evolution - Not a Revolution Class The Old The New Hormones/AR-Axis Keto +/- Prednisone Bicalutamide Abiraterone acetate Enzalutamide Bone targeted Zoledronic acid Denosumab Chemotherapy Docetaxel Mitoxantrone Docetaxel Cabazitaxel Radiopharmaceuticals Strontium-89 Samarium-153 Radium-223
64 The Disease Continuum in Prostate Cancer & Current Treatments Death PSA Local Therapy 1 st Line Hormonal Therapy/ Castration 2 nd line Hormonal Therapies Bicalutamide Flutamide Nilutamide, etc. Asymptomatic Enzalutamide Abiraterone Docetaxel + Prednisone Enzalutamide Cabazitaxel + Prednisone Abiraterone plus Prednisone Radium 223 Symptoms TOC Non-Metastatic Castration Sensitive Time Metastatic Castration Resistant For Educational Purposes Only Not For Promotional Use 65
65 Prostate Cancer
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationUntil 2004, CRPC was consistently a rapidly lethal disease.
Until 2004, CRPC was consistently a rapidly lethal disease. the entry in systemic disease is declared on a an isolated PSA recurrence after local treatment so!!! The management of CRPC and MCRPC is different
More informationAndrogens and prostate cancer: insights from abiraterone acetate and other novel agents
Androgens and prostate cancer: insights from abiraterone acetate and other novel agents Ian Davis Ludwig Institute for Cancer Research Austin Health, Melbourne, Australia Supported in part by an Australian
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationEvolution or revolution in the treatment of prostate cancer
Evolution or revolution in the treatment of prostate cancer de Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD Professor of Experimental Cancer Medicine Department of Medicine/ Drug Development Unit
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer January 13, 2017 Sindu Kanjeekal MD FRCPC Medical Oncology and Hematology Regional Systemic Quality Lead Erie St Clair Adjunct Professor Schulich School of Medicine and University
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationSecond line hormone therapies. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Second line hormone therapies Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationManagement of castrate resistant disease; after first line hormone therapy fails
Management of castrate resistant disease; after first line hormone therapy fails Dr. Syed A Hussain Clinical Senior Lecturer and Consultant in Medical Oncology University of Liverpool and Clatterbridge
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More information8/31/ ) Intermittent androgen deprivation in androgen-sensitive PCa. 1) Alpharadin (Ra223) in CRPC with bone metastases
Bruce J. Roth, M.D. Clinical Trials: Medivation, Oncogenix 1) Alpharadin (Ra223) in CRPC with bone metastases 2) Enzalutamide (MDV-31) in CRPC and prior docetaxel 3) Abiraterone in chemo-naïve CRPC 4)
More informationSOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc
SOGUG meeting New drugs after docetaxel chemotherapy in patient with mcrpc Stéphane OUDARD, MD, PhD Head of the Oncology department Georges Pompidou Hospital, Paris France University Rene Descartes, Paris
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationManagement of Incurable Prostate Cancer in 2014
Management of Incurable Prostate Cancer in 2014 Julie N. Graff, MD, MCR Portland VA Medical Center Assistant Professor of Medicine Knight Cancer Institute, OHSU 2014: Cancer Estimates Stage at Diagnosis
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationASCO 2012 Genitourinary tumors
ASCO 2012 Genitourinary tumors Post ASCO Bern 14-06-2012 Dr. med. Richard Cathomas leitender Arzt Onkologie, KSGR, Chur Renal cell cancer Changes in first line treatment? Prostate cancer 3 positive phase
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationHormonal Manipulations in CRPC. NW Clarke Professor of Urological Oncology Manchester UK
Hormonal Manipulations in CRPC NW Clarke Professor of Urological Oncology Manchester UK Standard Treatment of CRPC Pre 2004 (and in 2013?) PSA progression 99m Tc BS negative CT scan large lymph node component
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationCancer de la prostate métastatique: prise en charge précoce
Cancer de la prostate métastatique: prise en charge précoce Stéphane Oudard, MD, PhD Georges Pompidou Hospital, Oncology Department, Paris, France stephane.oudard@egp.aphp.fr SAGB.CAB.14.08.0382c 3/02/2016
More informationChemohormonal Therapy For Prostate Cancer. What is old, is new again!
Chemohormonal Therapy For Prostate Cancer What is old, is new again! Mount Tremblant January 20, 2017 Kala S. Sridhar MD, MSc, FRCPC Medical Oncologist, Princess Margaret Hospital Head, GU Medical Oncology
More informationSUMMARY. 3. Emerging understanding of mechanisms of resistance to current treatments
SUMMARY 1. Discuss the active agents in prostate cancer currently available in Australia 2. Celebrate the growing role for Prostate Medical Oncologists in Multi Disc Teams active treaments overall survival
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More information2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC
Ronald de Wit Erasmus MC Cancer Institute The Netherlands 2014 Treatment Paradigms in mcrpc Docetaxel in hormone sensitive PC Disclosures Sanofi ; research grant support, consultancy and speaker fees Astellas;
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationEarly Chemotherapy for Metastatic Prostate Cancer
Early Chemotherapy for Metastatic Prostate Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Smilow Cancer Center Yale University Medical Center Disclosure Consultant: Sanofi Aventis, Celgene,
More informationPaul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia
Paul F. Schellhammer, MD, FACS Professor Eastern Virginia Medical School Norfolk, Virginia 5-year prostate cancer specific survival rates have improved from 67% to 99% between 1974 and 2000 Excellent survival
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationPatients Living Longer: The Promise of Newer Therapies
Patients Living Longer: The Promise of Newer Therapies David M. Nanus, MD! Chief, Division of Hematology and Medical Oncology! Weill Cornell Medicine! New York Presbyterian Hospital!! Demographics 180,890
More informationHormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering
> Hormone sensitive prostate cancer To add abiraterone or docetaxel? Dr Lisa Pickering Disclosures Institutional Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific
More informationA Forward Look at Options for. In Prostate Cancer
A Forward Look at Options for Prostate Cancer Charles J Ryan, MD Associate Professor of Medicine Helen Diller Family Comprehensive Cancer Center University of California, San Francisco UC 1 SF UC SF Castration
More informationManagement of mcrpc: Hormonal therapy and treatment sequence for CRPC
Management of mcrpc: Hormonal therapy and treatment sequence for CRPC Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationModern Screening and Treatment of Advanced Prostate Cancer John Tuckey
Modern Screening and Treatment of Advanced Prostate Cancer John Tuckey Commonest male cancer - 2939 per year Third male cancer death 670 per year More die with it than of it but More people die of prostate
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationOptimizing Outcomes in Advanced Prostate Cancer
Optimizing Outcomes in Advanced Prostate Cancer Module 3: Focus on Recent CRPC Guidelines and Advanced Hormone-Sensitive Disease Sébastien J. Hotte, MD, MSc (HRM), FRCPC Medical Oncologist and Head, Phase
More informationAnti-Androgen Therapies for Prostate Cancer: A Focused Review
Anti-Androgen Therapies for Prostate Cancer: A Focused Review Nischala Ammannagari, MD, and Saby George, MD, FACP Abstract Among men in the United States, prostate cancer is the most common malignancy
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationmcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE
mcrpc 2014 TRA EVOLUZIONE E RIVOLUZIONE: COME ORIENTARSI NEL LABIRINTO DELLE TERAPIE IL CARCINOMA PROSTATICO, UNA MALATTIA ETEROGENEA? RAZIONALE E RISULTATI DEL TRATTAMENTO CHEMIOTERAPICO ASSOCIATO ALL
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationPhilip Kantoff, MD Dana-Farber Cancer Institute
CHEMOTHERAPY FOR MCRPC Philip Kantoff, MD Dana-Farber Cancer Institute Harvard Medical School 1 Disclosure of Financial Relationships With Any Commercial Interest Name Nature of Financial Commercial Interests
More informationMapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD
Mapping the Complexity of Androgen Signaling In Prostate Cancer Progression Eleni Efstathiou MD PhD The University of Athens Medical School Dept of Clinical Therapeutics Prostate Cancer Evolution Chemotherapy
More informationRoberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
Il Trattamento della Malattia CRPC metastatica Terapie Radiometaboliche Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena AIOM: Gestione ottimale del Paziente con Carcinoma della
More informationHormone therapy works best when combined with radiation for locally advanced prostate cancer
Hormone therapy works best when combined with radiation for locally advanced prostate cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Introduction Introduction 1/3 of patients
More informationMÉTASTASES OSSEUSES ET RADIUM 223
MÉTASTASES OSSEUSES ET RADIUM 223 Marie-Laure Amram Service d oncologie Hôpitaux Universitaires de Genève Forome du 21.05.2015 Radium-22:3:mécanisme d action Mécanisme d action Mécanisme d action Radium-223
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationMichiel H.F. Poorthuis*, Robin W.M. Vernooij*, R. Jeroen A. van Moorselaar and Theo M. de Reijke
First-line non-cytotoxic therapy in chemotherapynaive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials Michiel H.F. Poorthuis*, Robin
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationGU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer. Dr. Simon Yu Nov 18, 2017
GU Guidelines Update Meeting: M0 Castrate Resistant Prostate Cancer Dr. Simon Yu Nov 18, 2017 Faculty/Presenter Disclosure Faculty: Dr. Simon Yu Relationships with commercial interests: Grants/Research
More informationSequencing treatment for metastatic prostate cancer
11 Sequencing treatment for metastatic prostate cancer SOPHIE MERRICK, STYLIANI GERMANOU, ROGER KIRBY AND SIMON CHOWDHURY In the past 10 years there have been significant advances in the understanding
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationHave we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer?
Have we optimized the use of Androgen Receptor pathway targeted drugs in Castrate-Resistant Prostate Cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationAmerican Urological Association (AUA) Guideline
1 Approved by the AUA Board of Directors April 2014 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2014 by the American Urological
More informationThe Role of the Medical Oncologist in the Treatment of Prostate Cancer. Alireza saadat hematologist and oncologist
The Role of the Medical Oncologist in the Treatment of Prostate Cancer Alireza saadat hematologist and oncologist When should you see an oncologist? High risk localized disease Rising PSA after local therapy
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationPlease consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada BLADDER CANCER A MULTICENTRE, RANDOMIZED PLACEBO-CONTROLLED, DOUBLE-BLIND
More informationNew Treatment Options for Prostate Cancer
New Treatment Options for Prostate Cancer Moderator: Jeremy P. Goldberg, President, JPG Healthcare LLC Panelists: Philip Kantoff, MD, Director, Lank Center for Genitourinary Oncology, Dana- Farber Cancer
More informationASCO 2011 Genitourinary Cancer
ASCO 2011 Genitourinary Cancer Expanding Options for Chronic Diseases? Walter Stadler, MD, FACP University of Chicago Disclosures (All Non-University &/or Financial Dealings with Potential, Real, or Perceived
More informationADT vs chemo + ADT as initial treatment for advanced prostate cancer
ADT vs chemo + ADT as initial treatment for advanced prostate cancer By Hussein Khaled Prof. Medical Oncology Cairo University Possible Levels of Prostate Cancer At Diagnosis Local-Regional Disease Spread
More informationAdvanced Prostate Cancer. Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options
Advanced Prostate Cancer Searching for Optimal Therapy Sequence and Assessing Emerging Treatment Options Disclaimer This slide deck in its original and unaltered format is for educational purposes and
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationWhat will change for men with advanced prostate cancer in the next 24 months? ESO Observatory: Perspective on endocrine and chemotherapy agents
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr.Sternberg has received research funding for
More informationGroup Sequential Design: Uses and Abuses
Group Sequential Design: Uses and Abuses Susan Halabi Department of Biostatistics and Bioinformatics, Duke University October 23, 2015 susan.halabi@duke.edu What Does Interim Data Say? 2 Group Sequential
More informationINTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER
INTERGRATING NON- HORMONAL THERAPIES INTO PROSTATE CANCER Daniel George, MD Professor of Medicine and Surgery Director of Genitourinary Oncology Program Duke Cancer Institute 1 Disclosures Consultant:
More informationAmerican Urological Association (AUA) Guideline
1 Approved by the AUA Board of Directors May 2018 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2018 by the American Urological
More informationMedical Treatments for Prostate Cancer
Medical Treatments for Prostate Cancer Ian F Tannock MD, PhD Daniel E Bergsagel Professor of Medical Oncology, Princess Margaret Hospital and University of Toronto March 17, 2005 Brampton 1 A hypothetical
More informationCon$nuing Care for Your Pa$ents with Metasta$c CRPC
27 th Annual InternaAonal Prostate Cancer Symposium Update January 26, 2017 Con$nuing Care for Your Pa$ents with Metasta$c CRPC Michael S. Cookson, MD, MMHC Professor and Chair Department of Urology University
More informationProgress in Metastatic Prostate Cancer
Integrating Current & Novel Treatment Strategies for the Management of CRPC Charles J Ryan, MD Thomas Perkins Distinguished Professor of Medicine and Urology Helen Diller Family Comprehensive Cancer Center
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationBoard Review 2017: Prostate Cancer. Dana Rathkopf, MD Associate Attending
Board Review 2017: Prostate Cancer Dana Rathkopf, MD Associate Attending www.mskcc.org The Paradox of Prostate Cancer High prevalence in the general population: over diagnosis of clinically insignificant
More informationADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER. ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA
ADVANCES IN METASTATIC HORMONE-SENSITIVE PROSTATE CANCER ALICIA K. MORGANS, MD, MPH Associate Professor of Medicine Northwestern University, USA MAY 2018 DISCLAIMER Please note: The views expressed within
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationPresent and Future Perspectives in Treatment of mcrpc Patients
Present and Future Perspectives in Treatment of mcrpc Patients Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com Disclosures Astellas, Takeda, Janssen, Bouchara Recordati,
More informationInitial hormone therapy (and more) for metastatic prostate cancer
Initial hormone therapy (and more) for metastatic prostate cancer Silke Gillessen, MD Medical Oncology Kantonsspital St.Gallen Switzerland silke.gillessen@kssg.ch Conflicts of interest Speakers Bureau
More informationReview of the Stampede Results. Charles Ryan MD University of California San Francisco
Review of the Stampede Results Charles Ryan MD University of California San Francisco Se#ng and hypothesis Se
More informationManagement Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?
Clinical Medicine Insights: Oncology Consise Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Management Options in Advanced Prostate Cancer: What is
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationProstate Cancer: Vision of the Future By: H.R.Jalalian
1 H. R. Jalalian Hematologist&Oncologist Baqiyatallah University of Medical Sciences 2 State of the art: vision on the future Diagnosis Surgery Radiotherapy Medical Oncology 3 Early Detection PSA sensitivity
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More information